Status of cannabinoids for pain management
Dr. Lynn Webster of the Lifetree Pain Clinic in Salt Lake City, Utah reports from the American Academy of Pain Medicine meeting.
Effective?
“Newer compounds show promise for analgesic efficacy while reducing common side effects of dizziness, euphoria, fatigue, and nausea.”
Sativex is an oral spray containing 2.7 mg of delta-9-tetrahydrocannabinol (THC) and 2.5 mg of cannabidiol (CBD).
- Including CBD appears to reduce the psychoactive effects of THC.
- Intoxication was less than with oral THC, according to presenters at the meeting.
- With Sativex, patients can control the amount they use, with a resulting dose of approximately 20-30 mg/day of both THC and CBD.
Sativex is approved for use in Canada and being studied in the US. The situation in the UK appears political.
6/14/07 23:13 JR